NASDAQ · ARWR
Arrowhead Pharmaceuticals, Inc.
Healthcare · Biotechnology
$58.98▲ 1.65% ($0.96)at close
After hours$58.22▼ 1.29%7:30 PM ET
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
- 10-yr revenue CAGR
- 19.6%
- Ending operating margin
- 0.0%
- Discount rate
- 10.4%
USD · TTM ending Jun 30, 2026 · Price used $58.98 · Price Oct 26, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 49.39% over the last year. Revenue grew 16.85% over the trailing twelve months. Operating margin moved from -18.84% to -33.82%. Free cash flow declined 326.26% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -33.82%. A decisive move in revenue — currently up 16.85% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States.
Market multiples
Stock splits
Every 10 shares became 1
Every 65 shares became 1
Profitability & growth
Analyst consensus
16
Buy
6
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 24, 2026
Q4 FY26 · EPS est -$1.52 · Revenue est $61.2M
Same quarter, year over year
FY26 YTD n/mEach cell vs the same quarter a year earlier (the cell below) · Q1–Q3 combined -$2.07 vs $0.10 · 1 of 3 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
FY25
FY24
FY23
—
—
—
—
Fiscal year totals
- FY25
- -$0.08
- n/m
- FY24
- -$5.02
- —
n/m: last year’s figure was zero, a loss or too small to compare against
Q3 FY26
Reported Aug 4, 2026 · Latest
HoverTap a cell to inspect
Actual
-$1.36
Estimate
-$1.28
Year over year
n/m
Vs prior quarter
n/m
Institutional Sentiment
Arrowhead Pharmaceuticals, Inc. · ARWR
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.